Vimal Mehta, Ph.D.

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development and corporate fundraising. He is a Co-founder, Chairman of the Board and Chief Executive Officer of BioXcel Corporation. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at Inpharmatica Ltd. and Jubilant Life Sciences. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation. Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in chemistry at the University of Montpellier, France.

Frank D. Yocca, Ph.D.

Frank D. Yocca, Ph.D.

Chief Scientific Officer

Dr. Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high performance, world-class teams in drug discovery and development whose efforts have resulted in a number of prominent neuroscience products including Buspar®, Serzone® Abilify® and Heltioz®. Frank has held various leadership roles at Astrazeneca and Bristol Myers Squibb. He is a recognized scientific leader in the neuroscience community and member of the Institute of Medicine of the National Academy of Science, and a Fellow of the American College of Neuropsychopharmacology. He has 45 referred articles, 96 abstracts and 65 invited presentations. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology for St. John's University.

Vincent J.O'Neill M.D.

Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

Dr. O'Neill has proven expertise in therapeutic and diagnostic product development and has held senior leadership roles at global pharmaceutical companies, including Sanofi, Genentech and GlaxoSmithKline. Most recently, he served as Chief Medical Officer at Mirna Therapeutics and Exosome Diagnostics, where he oversaw global product development and medical affairs. At both Genentech and GlaxoSmithKline, he managed the clinical and biomarker development programs of several oncology therapeutic candidates. He was instrumental in the expanded approval of Genentech's Avastin® and Tarceva® oncology therapeutics. At GSK, he oversaw the signal transduction discovery unit and led the first IND application and clinical trial of the MEK inhibitor MEKINIST®. He has authored several peer-reviewed publications and conference presentations. Dr. O’Neill is also a member of the Royal College of Physicians. Dr. O’Neill received his M.D. and B.Sc. in molecular pathology from the University of Glasgow, Scotland.

Richard I. Steinhart

Richard I. Steinhart

Vice President & Chief Financial Officer

Mr. Steinhart brings significant financial and strategic experience in the biotechnology and medical device industries. Prior to joining BioXcel Therapeutics, Richard served as Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. Prior to joining Remedy Pharmaceuticals, Mr. Steinhart served as an independent consultant to biotechnology and medical device companies. Previously, Mr. Steinhart was the Senior Vice President, Finance and Chief Financial Officer of MELA Sciences. Prior to joining MELA Sciences, Mr. Steinhart held a variety of senior-level positions at Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies, Emisphere Technologies, Inc., and CW Group, Inc., a venture capital firm focused on medical technology. He began his career at PriceWaterhouseCoopers.

Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc. and Atossa Genetics, Inc. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant.

Chids Mahadevan

Chids Mahadevan

Vice President, Finance & Chief Accounting Officer

Mr. Mahadevan is responsible for leading the finance and accounting functions of the company and has extensive experience and knowledge of finance management in the software and pharmaceutical industries. Prior to joining BioXcel, Mr. Mahadevan was the Senior Vice President, Finance at GoldenSource Corp, an enterprise data management software company where he led the global finance and accounting team. Previously, he was the Director of Finance at inVentiv Health Inc. Mr. Mahadevan started his career at Ramco Systems, where he ultimately served as Head of Finance for the United States operations and the Finance Lead for the global aviation software segment. Mr. Mahadevan holds a B.S. in Commerce from Madras University. Mr. Mahadevan is a Certified Public Accountant in the United States and also a Chartered Accountant from India.

Chetan D. Lathia, Ph.D.

Senior Vice President & Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

Dr. Lathia has co-led the IND submissions for a number of new molecular entities and eight new drug applications (NDA) / biologics license application (BLA) in the US, Europe, Japan, China, etc. In addition to presenting clinical pharmacology & clinical strategy at meetings with drug regulators, he has made presentations to the Special Advisory Group (SAG) of the European Medicines Agency and an advisory meeting held by Taiwanese regulators. Dr. Lathia has delivered presentations to the Food and Drug Administration on invitation from the agency's Office of Clinical Pharmacology.

Most recently, Dr. Lathia served as the VP and Head of Clinical Pharmacology at Intarcia Therapeutics where he was responsible for leading the pharmacokinetics (PK)/pharmacodynamics (PD), immunogenicity and bioanalytical strategy. Prior to that, Dr. Lathia served as the Executive Director, Clinical Pharmacology at Alexion Pharmaceuticals where he led the global clinical and nonclinical PK/PD, pharmacometrics, and bioanalytics functions. Previously, Dr. Lathia served as the Global Head, Oncology Biomarkers and Pharmacokinetics and as the Global Clinical Pharmacology Leader for Nexavar at Bayer. Prior to this he was a Senior Research Associate at Parke-Davis Research where he co-led drug metabolism, nonclinical & clinical PK functions for the oncology & cardiovascular portfolio.

Dr. Lathia earned a doctorate in pharmacokinetics from Virginia Commonwealth University and a bachelor's in pharmacy, with a gold medal in pharmacology from L M College of Pharmacy, India.

Cedric Burg, Ph.D.

VP, Head of Global Clinical Operations and Project Management

Dr. Burg has over 20 years of experience in clinical operations and project management. Prior to joining BTI, Dr. Burg served as the head of clinical operations at Rocket Pharmaceuticals, where he was responsible for the overall clinical operations and program management. Prior to joining Rocket Pharmaceuticals, Cedric served as the vice president of clinical development and global project management at Chiltern International, a global contract research organization, where he was responsible for running the global late phase group, clinical development programs and managing projects across the company. Dr. Burg spent several years at Teva Pharmaceuticals and played a key role in the execution and delivery of worldwide clinical programs. As the Company's deputy head of global clinical operations, he was responsible for global operations and clinical development strategy across several geographies. Prior to that, Dr. Burg was the director of clinical trials and director of medical affairs at Teva Pharmaceuticals for Spain. Additionally, Dr. Burg has held key positions in clinical trial management at Bristol Myers Squibb and Phidea, a contract research organization.

Dr. Burg received a bachelor's degree in biology and life sciences from the American University, Washington D.C. and a master's degree in molecular and cellular biology from Rennes University, France. He earned his Ph.D. in molecular and cellular biology from Nantes University, France. He has authored several peer-reviewed publications and conference presentations.

Vikas Sharma, Ph.D.

Vice President of Business Development

Dr. Sharma has over 12 years of experience in business development activities across the pharma landscape. He has led multiple complex deals that involved upfront, milestone and royalty payments. Most recently Dr. Sharma was the director, business development at MacroGenics where he played an instrumental role in leading licensing deals with companies such as Incyte Corporation, Roche, and Janssen Pharmaceuticals. Prior to joining MacroGenics, Dr. Sharma served as the director, business development at Rexahn Pharmaceuticals where he led the due diligence and execution of licensing deals, M&A as well as capital markets transactions. Previously, he served as manager, business development for MedImmune (the global biologics business of AstraZeneca), where he executed multiple licensing transactions. Prior to that, Dr. Sharma served in a business development role with increasing responsibilities at Children's Hospital of Philadelphia, Bradley Pharmaceuticals and Advanced Bioadjuvant.

Dr. Sharma earned a second master's degree and a doctorate in biology from Rutgers University. He completed his bachelor's degree and master's degree in microbiology from the University of Mumbai, India. He has authored multiple peer-reviewed publications and conference presentations.

Michael De Vivo Ph.D.

Vice President, Neuroscience

Dr. De Vivo has over 15 years of experience in neuroscience drug discovery and clinical development. He has a proven track record of leading project teams and advancing compounds from early stage discovery through proof-of-concept clinical trials. Prior to joining BTI, Mike served as a director of neuroscience at Pfizer, where he was responsible for leading the translational research and preclinical studies for therapeutic assets, as well as overseeing the Parkinson's disease project. Prior to joining Pfizer, he served as the Vice President of pharmacology at Memory Pharmaceuticals, where he was responsible for building a clinical development plan for MEM1414, a PDE4 inhibitor being developed for Alzheimer's Disease. Additionally, he led the partnering of Memory Pharmaceuticals' schizophrenia drug with Amgen and managed the Company's biology department. Previously, Dr. De Vivo served as the group leader of assay development at Trophix Pharmaceuticals, where he developed new assays and secured corporate partnerships for the company. Earlier in his career, Dr. De Vivo was an adjunct research assistant professor in the department of pharmacology at Mount Sinai School of Medicine.

Dr. De Vivo received a bachelor's degree in chemistry from the Rutgers College. He earned his Ph.D. in biomedical sciences from Mount Sinai School of Medicine and completed his postdoctoral fellowship at Cornell University. He has authored several peer-reviewed publications.

David C. Hanley

Vice President and Head of Global Pharmaceutical Development and Operations

Dr. Hanley has 17 years of experience in Chemistry, Manufacturing and Controls (CMC) and Technical Operations functions and cross-functional development teams in the U.S. and Europe. Most recently, Dr. Hanley was the Vice President of Pharmaceutical Sciences at Radius Health Inc. (NASDAQ: RDUS), subsequent to serving as Executive Director of Technical Operations, where he was responsible for technical development, CMC Regulatory approval and a successful commercial launch in the US. Prior to joining Radius Health, Dr. Hanley served in various roles of increasing responsibility, including Senior Director, Global Pharmaceutical Development at The Medicines Company and Global Program Management roles at each of The Medicines Company, Medarex Inc. and Schering AG. Dr. Hanley began his career in CMC development at Berlex Laboratories / Schering A.G. in the US and in Europe.

Dr. Hanley received his bachelor's degree in chemistry from Virginia Commonwealth University. He earned a doctorate in physical and analytical chemistry from University of Utah. He has authored multiple peer-reviewed publications, conference presentations, and patents.